Research
A small-molecule compound (not actually a peptide) that blocks an enzyme tied to fat storage. Popular in longevity circles, but only tested in animals so far.
Weight Management & Obesity
Research
A lab-made fragment of growth hormone, designed to burn fat without any of growth hormone's other effects. Human trials didn't show it actually works better than placebo.
Clinical Trials
A long-acting amylin-mimicking peptide best known as half of Novo Nordisk's CagriSema combo. Works alongside GLP-1 drugs to suppress appetite even further.
Research
A long-acting growth hormone booster, often paired with Ipamorelin for steady, round-the-clock growth hormone support.
Research Phase
A dual GLP-1/glucagon receptor agonist approved in China for weight management, combining appetite suppression with increased energy expenditure.
Clinical Trials
An experimental triple-hormone injection from Eli Lilly showing the biggest weight-loss results of any drug tested so far. Not yet approved — still in late-stage trials.
FDA Approved
The FDA-approved GLP-1 behind Ozempic and Wegovy. Reduces appetite, blood sugar, and heart disease risk.
Research Phase
An investigational dual GLP-1/glucagon receptor agonist in Phase 3 trials, designed to combine appetite suppression with increased calorie burning.
FDA Approved
One of the few growth-hormone peptides that's actually FDA approved — but only for a specific fat-redistribution condition in HIV patients. Any other use is off-label.
FDA Approved
An FDA-approved weekly injection for diabetes and weight loss. Delivers the strongest results of any approved weight-loss medication to date.